| 1. |
- Becker, Charlotte, et al.
(författare)
-
Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer.
- 2003
-
Ingår i: Journal of Urology. - : Ovid Technologies (Wolters Kluwer Health). - 1527-3792 .- 0022-5347. ; 170:4 Pt 1, s. 1169-1174
-
Tidskriftsartikel (refereegranskat)abstract
- Purpose: We investigated the value of serum measurements for glandular kallikrein 2 (hK2), and free (f) and total (t) prostate specific antigen (PSA) in a second round of biannual screening for prostate cancer. Materials and Methods: In 1995 to 1996, 5,853 of 9,811 randomly selected men in Goteborg, Sweden 50 to 66 years old had PSA measurements. Of 660 men 611 with tPSA 3 ng/ml or greater underwent biopsy and 145 had cancer. All were re-invited 2 years later for PSA testing, and 506 of 596 men with tPSA 3 ng/ml or greater underwent biopsy and 113 cancers were detected. We analyzed hK2, tPSA and fPSA in 423 of 453 (93%) men who underwent biopsy in 1997 to 1998 who were also screened in 1995 to 1996. Results: The 99 of 423 (23%) men who underwent biopsy diagnosed with prostate cancer in 1997 to 1998 had significantly different tPSA, percent fPSA and hK2 x tPSA/fPSA compared to the men with negative biopsies from 2 years earlier. The largest area under curve was obtained for hK2 x tPSA/fPSA in serum from 1995 to 1996 and from 1997 to 1998, but the difference was not significant compared to tPSA and percent fPSA. In serum from 1997 to 1998 measurements of hK2 x tPSA/fPSA gave significantly higher specificity than tPSA at 85% sensitivity, and significantly higher specificity than tPSA and percent fPSA at 70% to 75% sensitivity. In addition, levels of hK2 and hK2 x tPSA/fPSA manifested a significantly greater 2-year increase in men with cancer compared to those with benign biopsies. Conclusions: In men with tPSA levels 3.0 ng/ml or greater who were not diagnosed with cancer during a first round of screening, hK2 measurements enhanced specificity compared to tPSA testing at moderately high sensitivity, and manifested a greater 2-year increase in men with cancer.
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
- Golman, Klaes, et al.
(författare)
-
13C-angiography.
- 2002
-
Ingår i: Academic Radiology. - 1878-4046. ; 9:Suppl 2, s. 507-510
-
Tidskriftsartikel (refereegranskat)
|
|
| 5. |
|
|
| 6. |
- Holmström, Anna, et al.
(författare)
-
LcrV is a channel size-determining component of the Yop effector translocon of Yersinia
- 2001
-
Ingår i: Molecular Microbiology. - : Blackwell Publishing. - 0950-382X .- 1365-2958. ; 39:3, s. 620-632
-
Tidskriftsartikel (refereegranskat)abstract
- Delivery of Yop effector proteins by pathogenic Yersinia across the eukaryotic cell membrane requires LcrV, YopB and YopD. These proteins were also required for channel formation in infected erythrocytes and, using different osmolytes, the contact‐dependent haemolysis assay was used to study channel size. Channels associated with LcrV were around 3 nm, whereas the homologous PcrV protein of Pseudomonas aeruginosa induced channels of around 2 nm in diameter. In lipid bilayer membranes, purified LcrV and PcrV induced a stepwise conductance increase of 3 nS and 1 nS, respectively, in 1 M KCl. The regions important for channel size were localized to amino acids 127–195 of LcrV and to amino acids 106–173 of PcrV. The size of the channel correlated with the ability to translocate Yop effectors into host cells. We suggest that LcrV is a size‐determining structural component of the Yop translocon.
|
|
| 7. |
|
|
| 8. |
|
|
| 9. |
- Melin, L G, et al.
(författare)
-
Evaluation of four composite shear test methods by digital speckle strain mapping and fractographic analysis
- 2000
-
Ingår i: Journal of composites technology & research. - 0884-6804 .- 1945-7537. ; 22:3, s. 161-172
-
Tidskriftsartikel (refereegranskat)abstract
- Four methods to determine composite interlaminar shear strength (ILSS) are evaluated. In particular, the recently devised inclined double-notch shear test (IDNS) is compared with three existing and more established methods: the Iosipescu test, the short three-point bending test (S3PB) and the double-notch compression test (DNC). The uniformity of strain field in the test region in a real test situation-which is the crucial test method quality parameter-is investigated by strain mapping using digital speckle photography. The measured strain fields are compared with FE-calculated strains representing ideal conditions and both known advantages and drawbacks of the different methods are confirmed. The IDNS test produces the most uniform strain fields and also consistently high ILSS values. A fractographic analysis indicates shear separation over a major part of the fracture surfaces of all specimen types; typical shear cusps were found over about 80% of the IDNS fracture surface and in about 50% to 70% in the other specimens. For the Iosipescu tests, failure initiation could be ascribed to initiation in tension at defects. Experimentally determined stress-strain responses in shear exhibit a distinct variation among the different methods. For the best methods, a notable material softening was observed Drier to failure. Observed formation of shear cusps is believed to be the primary cause for this softening of the composite material studied here.
|
|
| 10. |
- Nurmikko, Pauliina, et al.
(författare)
-
Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146
- 2001
-
Ingår i: Clinical Chemistry. - 0009-9147. ; 47:8, s. 1415-1423
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND: The proportion of free prostate-specific antigen (PSA) is higher in the sera of patients with benign prostatic hyperplasia compared with patients with prostate cancer (PCa). We developed an immunoassay that measures intact, free PSA forms (fPSA-I), but does not detect free PSA that has been internally cleaved at Lys145-Lys146 (fPSA-N), and investigated whether this form could discriminate patients with PCa from those without PCa. METHODS: The assay for fPSA-I uses a novel monoclonal antibody (MAb) that does not detect PSA that has been internally cleaved at Lys145-Lys146. A MAb specific for free PSA was used as a capture antibody, and purified recombinant proPSA was used as a calibrator. The concentrations of fPSA-I, free PSA (PSA-F), and total PSA (PSA-T) were analyzed in EDTA-plasma samples (n = 276) from patients who participated in a screening program for PCa (PSA-T, 0.83-76.3 microg/L). RESULTS: The detection limit of the fPSA-I assay was 0.035 microg/L. Both the measured concentrations of fPSA-I and the concentrations of fPSA-N (calculated as PSA-F - fPSA-I) provided statistically significant discrimination of the two clinical groups. By contrast, PSA-F did not discriminate between these groups. Each of the ratios fPSA-I/PSA-F, fPSA-N/PSA-T, and PSA-F/PSA-T separated cancer samples from noncancer samples in a statistically significant manner (P <0.0001). The ratio fPSA-I/PSA-F was significantly higher in cancer (median, 59%) compared with noncancer samples (47%). CONCLUSIONS: The ratio fPSA-I/PSA-F is significantly higher in cancer compared with noncancer. The percentages of both fPSA-N/PSA-T and fPSA-I/PSA-F may provide interesting diagnostic enhancements alone or in combination with other markers and require further studies.
|
|
